For describing the patterns of drug use within patients who have multiple sclerosis using the disease-modifying drugs and for the estimation of occurrence of various hostile events of the treatment a combined study was conducted in collaboration with the German Pharmacoepidemiological Research Database between 1st January of 2006 and 31st December of 2013.
MS patients who are basically patients classified with having an invisible illness, on DMDs were explained in terms of the patterns of drug usage and the characteristics of their clinical trial. After this, the assessment of the incidence of the AEs took place in the new users.
Amongst about 11M members who were insured of the German Statutory Health Insurance, the users of DMD were comprised of 15,377 patients with the MS, with an average age of thirty-nine years and sixty-eight percent were females.
The general rate of the relapses of MS per patient and per year was 0.34. for the average period of follow up of 1650 days, the DMD treatment was more common amongst MS patients i.e. 42.4 %, this was followed by the intruding treatment of patients i.e. 39.5% were interrupters. Very less common was the switching of the DMD treatment 11.9%. Lastly, there were only 5.6% of the patients who terminated the treatment.
The rate of the occurrence of all negative events was not varying significantly across the different DMDs.
Hence, it can be concluded that the discontinuation of the treatment with the DMDs and switching off the treatment barely occurs. The reasons and causes why there is a frequent interruption in the DMD-treatment are still to be examined and studied by collecting the primary data. Large data sets are required for the active monitoring of the new DMDs.